What is the recommended dose of cabozantinib in patients with lung adenocarcinoma?

Regarding the recommended dose of cabozantinib for patients with lung adenocarcinoma, according to publicly released information, the recommended dose of cabozantinib for advanced non-small cell lung cancer (including lung adenocarcinoma) is usually 60 mg per day.

Specifically, cabozantinib is a multi-target tyrosine kinase inhibitor that achieves anti-tumor effects by inhibiting multiple kinases related to tumor growth and angiogenesis. Cabozantinib can be an effective treatment option in the treatment of lung adenocarcinoma, especially in patients who have experienced disease progression following other treatments.

Regarding the method of taking cabozantinib, it is generally recommended to do so under the guidance of an experienced doctor. The drug is available in capsule and tablet form, with different dosage strengths including 20 mg, 40 mg, 60 mg and 80 mg. For patients with lung adenocarcinoma, a dose of 60 mg per day is an effective dose proven in clinical studies.

In addition, cabozantinib is generally recommended to be taken on an empty stomach, that is, at least 2 hours before a meal or 1 hour after a meal to ensure optimal absorption and utilization of the drug.

Cabozantinib may cause a series of side effects, such as diarrhea, stomatitis, hand and foot skin reactions, etc. Patients should pay close attention to body reactions and promptly report any discomfort to their doctor. The doctor will adjust the drug dosage or provide corresponding supportive treatment according to the specific situation.

While taking cabozantinib, patients need to undergo regular examinations to evaluate the efficacy and safety of the drug. These tests may include blood tests, imaging tests, etc.